Bisphosphonates associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time

Samantha Pozzi, Raffaella Marcheselli, Simona Falorio, Luciano Masini, Caterina Stelitano, Antonietta Falcone, Giovanni Quarta, Luisa Ponchio, Vincenzo Pitini, Stefano Luminari, Luca Baldini

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aims of the study were long term follow-up (FU) of bisphosphonates- associated osteonecrosis of the jaw (ONJ) in 35 cases observed by Gruppo Italiano Studio Linfomi (GISL) between 2002 and 2005 and the evaluation of its frequency in multiple myeloma patients over time. We asked the centres to up-date cases with ONJ, and to report new cases of ONJ diagnosed between 2006 and 2008. After a median FU of 31 months, 19 patients are alive, 13 died, mainly from progression of the primary disease, and three patients are lost to follow-up. Treatment was mainly conservative, however, nine patients underwent surgery. Overall improvement was reported in 13 patients, 11 stabilized, and eight patients progressed. One patient relapsed after dental procedure. ONJ impacted quality of life, causing pain and interfering with the ability to eat. Although the frequency of ONJ in myeloma patients in the period 2006-2008 was slightly increased (3.6% vs. 1.9% in 2002-2005), we confirm the rarity of the complication.

Original languageEnglish
Pages (from-to)850-852
Number of pages3
JournalAmerican Journal of Hematology
Volume84
Issue number12
DOIs
Publication statusPublished - Dec 2009

Fingerprint

Bisphosphonate-Associated Osteonecrosis of the Jaw
Osteonecrosis
Jaw
Aptitude
Lost to Follow-Up
Multiple Myeloma
Disease Progression
Tooth
Quality of Life
Pain

ASJC Scopus subject areas

  • Hematology

Cite this

Bisphosphonates associated osteonecrosis of the jaw : A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time. / Pozzi, Samantha; Marcheselli, Raffaella; Falorio, Simona; Masini, Luciano; Stelitano, Caterina; Falcone, Antonietta; Quarta, Giovanni; Ponchio, Luisa; Pitini, Vincenzo; Luminari, Stefano; Baldini, Luca.

In: American Journal of Hematology, Vol. 84, No. 12, 12.2009, p. 850-852.

Research output: Contribution to journalArticle

Pozzi, Samantha ; Marcheselli, Raffaella ; Falorio, Simona ; Masini, Luciano ; Stelitano, Caterina ; Falcone, Antonietta ; Quarta, Giovanni ; Ponchio, Luisa ; Pitini, Vincenzo ; Luminari, Stefano ; Baldini, Luca. / Bisphosphonates associated osteonecrosis of the jaw : A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time. In: American Journal of Hematology. 2009 ; Vol. 84, No. 12. pp. 850-852.
@article{1bc780b776c446d7bdf4b8e1de4d5762,
title = "Bisphosphonates associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time",
abstract = "Aims of the study were long term follow-up (FU) of bisphosphonates- associated osteonecrosis of the jaw (ONJ) in 35 cases observed by Gruppo Italiano Studio Linfomi (GISL) between 2002 and 2005 and the evaluation of its frequency in multiple myeloma patients over time. We asked the centres to up-date cases with ONJ, and to report new cases of ONJ diagnosed between 2006 and 2008. After a median FU of 31 months, 19 patients are alive, 13 died, mainly from progression of the primary disease, and three patients are lost to follow-up. Treatment was mainly conservative, however, nine patients underwent surgery. Overall improvement was reported in 13 patients, 11 stabilized, and eight patients progressed. One patient relapsed after dental procedure. ONJ impacted quality of life, causing pain and interfering with the ability to eat. Although the frequency of ONJ in myeloma patients in the period 2006-2008 was slightly increased (3.6{\%} vs. 1.9{\%} in 2002-2005), we confirm the rarity of the complication.",
author = "Samantha Pozzi and Raffaella Marcheselli and Simona Falorio and Luciano Masini and Caterina Stelitano and Antonietta Falcone and Giovanni Quarta and Luisa Ponchio and Vincenzo Pitini and Stefano Luminari and Luca Baldini",
year = "2009",
month = "12",
doi = "10.1002/ajh.21553",
language = "English",
volume = "84",
pages = "850--852",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Bisphosphonates associated osteonecrosis of the jaw

T2 - A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time

AU - Pozzi, Samantha

AU - Marcheselli, Raffaella

AU - Falorio, Simona

AU - Masini, Luciano

AU - Stelitano, Caterina

AU - Falcone, Antonietta

AU - Quarta, Giovanni

AU - Ponchio, Luisa

AU - Pitini, Vincenzo

AU - Luminari, Stefano

AU - Baldini, Luca

PY - 2009/12

Y1 - 2009/12

N2 - Aims of the study were long term follow-up (FU) of bisphosphonates- associated osteonecrosis of the jaw (ONJ) in 35 cases observed by Gruppo Italiano Studio Linfomi (GISL) between 2002 and 2005 and the evaluation of its frequency in multiple myeloma patients over time. We asked the centres to up-date cases with ONJ, and to report new cases of ONJ diagnosed between 2006 and 2008. After a median FU of 31 months, 19 patients are alive, 13 died, mainly from progression of the primary disease, and three patients are lost to follow-up. Treatment was mainly conservative, however, nine patients underwent surgery. Overall improvement was reported in 13 patients, 11 stabilized, and eight patients progressed. One patient relapsed after dental procedure. ONJ impacted quality of life, causing pain and interfering with the ability to eat. Although the frequency of ONJ in myeloma patients in the period 2006-2008 was slightly increased (3.6% vs. 1.9% in 2002-2005), we confirm the rarity of the complication.

AB - Aims of the study were long term follow-up (FU) of bisphosphonates- associated osteonecrosis of the jaw (ONJ) in 35 cases observed by Gruppo Italiano Studio Linfomi (GISL) between 2002 and 2005 and the evaluation of its frequency in multiple myeloma patients over time. We asked the centres to up-date cases with ONJ, and to report new cases of ONJ diagnosed between 2006 and 2008. After a median FU of 31 months, 19 patients are alive, 13 died, mainly from progression of the primary disease, and three patients are lost to follow-up. Treatment was mainly conservative, however, nine patients underwent surgery. Overall improvement was reported in 13 patients, 11 stabilized, and eight patients progressed. One patient relapsed after dental procedure. ONJ impacted quality of life, causing pain and interfering with the ability to eat. Although the frequency of ONJ in myeloma patients in the period 2006-2008 was slightly increased (3.6% vs. 1.9% in 2002-2005), we confirm the rarity of the complication.

UR - http://www.scopus.com/inward/record.url?scp=73349097839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349097839&partnerID=8YFLogxK

U2 - 10.1002/ajh.21553

DO - 10.1002/ajh.21553

M3 - Article

C2 - 19862827

AN - SCOPUS:73349097839

VL - 84

SP - 850

EP - 852

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 12

ER -